Mixed Insulins Pick Me

Similar documents
Basal Insulin Drug Class Prior Authorization Protocol

Update on New Basal Insulins and Combinations: Starting, Titrating and Adding to Therapy

Newer Insulins. Boca Raton Regional Hospital 15th Annual Internal Medicine Conference

Insulin Prior Authorization with optional Quantity Limit Program Summary

INSULIN 101: When, How and What

Type 2 Diabetes Mellitus Insulin Therapy 2012

Initiation and Adjustment of Insulin Regimens for Type 2 Diabetes

Comprehensive Diabetes Treatment

Objectives. Navigating New Insulins. Disclosures. Diabetes: The Stats. Normal Insulin Release Individuals without diabetes. History of Insulin 5/23/17

Tips and Tricks for Starting and Adjusting Insulin. MC MacSween The Moncton Hospital

PHARMACISTS INTERACTIVE EDUCATION CASE STUDIES

Lantus to levemir conversion

Initiation and Titration of Insulin in Diabetes Mellitus Type 2

8/13/2016. Insulin Basics. Rapid-Acting Insulin Analogs. Current Insulin Products and Pens. Basal Insulin Analogs. History of Insulin Therapy

Drug Effectiveness Review Project Summary Report Long acting Insulins

PHARMACISTS INTERACTIVE EDUCATION CASE STUDIES

Beyond Basal Insulin: Intensification of Therapy Jennifer D Souza, PharmD, CDE, BC-ADM

Timely!Insulinization In!Type!2! Diabetes,!When!and!How

New Drug Evaluation: Insulin degludec/aspart, subcutaneous injection

LET S TALK INSULIN THE BASICS

ClinicalTrials.gov Identifier: sanofi-aventis. Sponsor/company:

Update on Insulin-based Agents for T2D. Harry Jiménez MD, FACE

Agenda. Indications Different insulin preparations Insulin initiation Insulin intensification

Basal-Bolus Insulin Therapy. Veronica Brady, PhD, FNP-BC, BC-ADM, CDE ECHO January

New Therapies for Diabetes Management: Hope or Headache?

Short-acting insulins. Biphasic insulins. Intermediate- and long-acting insulins

Diabetes in Pregnancy

Insulin Basics. Bryan Primary Care Conference May 21, 2016 Shannon Wakeley MD Complete Endocrinology

Converting lantus to humalog 75 25

UKPDS: Over Time, Need for Exogenous Insulin Increases

Inpatient Glycemic Management:

Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial Treatment Protocols. Askiel Bruno, MD, MS Protocol PI

Management of Diabetes New Concepts New Devices New Medications. Richard J. Comi, MD Professor of Medicine Geisel School of Medicine at Dartmouth

These Aren t Your Average Rookies: A Primer on New and Emerging Insulins. Alissa R. Segal, Pharm.D, CDE, CDTC, FCCP

Conversion from lantus to tresiba

Disclosure 1/16/2017. Michael R. Brennan D.O., M.S., F.A.C.E Director Beaumont Endocrine Center Chief of Endocrine Beaumont Grosse Pointe 1/16/2017 2

Learning Objectives. Perioperative SWEET Success

Adjusting Insulin Doses

Diabetes Head to Toe May 31, 2017

Safe use of insulin regular concentrated (500 units/ml) in severe insulin resistance

Learning Objectives. Outline 4/3/2018. Treatment Strategies to Maximize the Value of Diabetes Medications

INSULIN INITIATION AND INTENSIFICATION WITH A FOCUS ON HYPOGLYCEMIA REDUCTION

Learning Objectives. Are you ready for more insulin formulations?

Antihyperglycemic Agents in Diabetes. Jamie Messenger, PharmD, CPP Department of Family Medicine East Carolina University August 18, 2014

Sponsor / Company: Sanofi Drug substance(s): Insulin Glargine (HOE901) Insulin Glulisine (HMR1964)

Insulin Initiation and Intensification. Disclosure. Objectives

INSULIN IN THE OBESE PATIENT JACQUELINE THOMPSON RN, MAS, CDE SYSTEM DIRECTOR, DIABETES SERVICE LINE SHARP HEALTHCARE

Initiating Injectable Therapy in Type 2 Diabetes

Poll Question 2. Special Boot Camp Workshop Beverly Dyck Thomassian, RN, MPH, BC ADM, CDE President, Diabetes Education Services.

nocturnal hypoglycemia percentage of Hispanics in the insulin glargine than NPH during forced patients who previously This study excluded

Insulin Prior Authorization Criteria For Individuals Who Purchased BlueCare/KS Solutions/EPO Products

Update on Insulin-based Agents for T2D

New basal insulins Are they any better? Matthew C. Riddle, MD Professor of Medicine Oregon Health & Science University Keystone Colorado 15 July 2011

Objectives 2/13/2013. Figuring out the dose. Sub Optimal Glycemic Control: Moving to the Appropriate Treatment

Providing Stability to an Unstable Disease

Nph insulin conversion to lantus

Opinion 18 December 2013

What s New in Type 2 Diabetes? 2018 Diabetes Updates

Drug Use Criteria: Exogenous Insulin Products

Insulin Prior Authorization Criteria For Individuals who Purchased BlueCare / KS Solutions products

Sponsor / Company: Sanofi Drug substance(s): insulin glargine (HOE901) According to template: QSD VERSION N 4.0 (07-JUN-2012) Page 1

Position Statement of ADA / EASD 2012

Reviewing Diabetes Guidelines. Newsletter compiled by Danny Jaek, Pharm.D. Candidate

Objectives. Recognize all available medical treatment options for diabetes. Individualize treatment and glycemic target based on patient factors

5/16/2018. Insulin Update: New and Emerging Insulins. Disclosures to Participants. Learning Objectives

Type I Type II Insulin Resistance

Insulins: Prices, Rebates, and Other Factors Influencing Costs. May 2018

In-hospital management of diabetes

OTE HAR M A. Insulin degludec (Tresiba ): Ultralong. basal insulin with less nocturnal hypoglycemia than glargine.

Important Stuff. Basal Bolus What Adjustments? Pt weighs 80kg

Case Study: Competitive exercise

AACN PCCN Review. Endocrine

Emerging Challenges in Primary Care: Safely Achieving Goals in Type 2 Diabetes (T2D): The Role of Concentrated and Long-Acting Insulins

BRIAN MOSES, MD, FRCPC (INTERNAL MEDICINE) CHIEF OF MEDICINE, SOUTH WEST HEALTH

Insulin Regimens: Hitting Glycemia Targets

APPENDIX American Diabetes Association. Published online at

Lantus levemir conversion

The New Age of Insulin: Exploring the Latest Trends in Insulin Therapy. The New Age of Insulin: Exploring the Latest Trends in Insulin Therapy

The York Diabetes Care Model

INSULIN THERAY دکتر رحیم وکیلی استاد غدد ومتابولیسم کودکان دانشگاه علوم پزشکی مشهد

Society for Ambulatory Anesthesia Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery

All Things Insulin: Dosing, Monitoring, Titrating, Transitioning

Degludec lantus conversion

6/5/18. Emerging Challenges in Primary Care: Safely Achieving Goals in Type 2 Diabetes (T2D): The Role of Concentrated and Long- Acting Insulins

Sponsor / Company: Sanofi Drug substance(s): Insulin Glargine. According to template: QSD VERSION N 4.0 (07-JUN-2012) Page 1

Self-Monitoring Blood Glucose (SMBG) Frequency & Pattern Tool

Injecting Insulin into Out Patient Practice

Inpatient Management of Hyperglycemia Guillermo Umpierrez, MD, CDE Saturday, February 10, :30 a.m. 11:15 a.m.

Toujeo to lantus conversion

Sponsor / Company: Sanofi Drug substance(s): HOE901-U300 (insulin glargine)

Individualising Insulin Regimens: Premixed or basal plus/bolus?

What's New in Insulin Related Therapies 2018

What s New in Type 2 Diabetes? 2018 Diabetes Updates

Blood Sugar and Insulin

第十五章. Diabetes Mellitus

Basal Bolus Insulin Therapy Frequently Asked Questions

Brigham and Women s Hospital Type 2 Diabetes Management Program Physician Pharmacist Collaborative Drug Therapy Management Protocol

24 Hour Support. Telephone Available 24 hours a day, 7 days a week

Long-Acting Human Insulin Analogs Created: June 2014

IT S MORE OF AN ART : MANAGING INSULIN THERAPY IN THE OLDER PATIENT

Transcription:

Mixed Insulins Pick Me Alvin Goo, PharmD Clinical Associate Professor University of Washington School of Pharmacy and Department of Family Medicine Objectives Critically evaluate the evidence comparing the efficacy and safety of mixed versus basal analogs. Discuss advantages and disadvantages of mixed versus basal analogs. Apply your knowledge and assist providers with adjusting mixed insulin. 1

Case The provider requests your recommendation regarding which insulin to initiate. 37 yo male with increasing symptoms of hyperglycemia. Recent A1c 10.8% Metformin ER 500mg 2tabs twice daily Glipizide 10mg twice daily Indapamide 2.5mg daily Gather information Information and risk for hypoglycemia Complete medication list (OTC, supplements) Renal function Neuropathy Current glycemic control Hx of Cardiovascular disease Meals / Nutrition Daily routine, work Vision Dexterity 2

Basal Analogs Mixed insulins Case How about starting glargine (basal analog)? Daily, easier for the patient to self administer Efficacious Safer; less hypoglycemia, peak less therefore safer 3

Basal analogs versus mixed insulin Efficacy Ease of administration Safety (risk for hypoglycemia) A) Degludec B) Detemir C) Glargine D) Mixed insulin E) NPH Insulin parameters Onset Peak effect Duration of action NPH 1 2hrs 4 10hrs 14 20hrs NPH 70/30 30 60min 2 12hrs Up to 20hrs Mixed analogs 10 30min 1 4hrs Up to 20hrs Glargine 1 3hrs Flat, Max in 5hrs 18 26hrs Insulin Detemir 1 3hrs Max in 5hrs 18 26hr Insulin Degludec 1 3hrs No Peak >24hrs Degludec / Aspart 70/30 5 30mins ½ 2hrs >24hrs 4

Glargine versus Degludec Haahr H, Heise T. Clin Pharmacokinet 2014;53(9):787 Degludec Haahr H, Heise T. Clin Pharmacokinet 2014;53(9):787 Risk of hypoglycemia NPH Basal Analogs A) < 10% A) < 10% B) 11 20% B) 11 20% C) 21 40% C) 21 40% D) 41 50% D) 41 50% E) > 50% E) > 50% 5

Lantus Package Insert Lantus n=357 NPH n=389 Severe 9 (2.5%) 7 (1.8%) NS Hypoglycemia Nocturnal 94 (25.6%) 136 (35%) 0.0049 Symptoms Weight (Kg) +3 +2.8 NS Severe symptomatic hypoglycemia was defined as an event with symptoms consistent with hypoglycemia requiring the assistance of another person and associated with either a blood glucose below 50 mg/dl Nocturnal symptomatic hypoglycemia as defined as symptoms which occurred while the patient was asleep between bedtime and before getting up in the morning p Newer Lantus package insert Severe hypoglycemia type 2 diabetes 52 weeks Oral combination 28 weeks with regular insulin 5years with regular insulin Lanutus NPH Lantus NPH Lantus NPH Rate 1.7% (5/289) 1.1% (3/281) 0.4% (1/259) 2.3% (6/259) 7.8% (40/513) 11.9% (60/504) http://products.sanofi.us/lantus/lantus.html#s5.2 Rates of hypoglycemia Glargine versus NPH studies Study Name Types of Hypoglycemia Rates of Hypoglycemia by type Eliaschewitz (24 weeks) Symptomatic Nocturnal symptomatic Confirmed nocturnal symptoms Severe symptomatic Fritsche (24 weeks) All episodes All episodes of symptomatic Nocturnal Severe Rosenstock (28 weeks) Symptomatic Nocturnal Severe Hsia (24 weeks) Symptomatic Nocturnal Fasting Severe Glargine QHS NPH QHS p value 52.8 % 20.4 % 16.9 % 2.6 % QHS 68 % 43 % 23 % 1.8 % QAM 74 % 56 % 17 % 2.1 % 61.3% 31.3 % 0.04 % (n=1) QHS 6.7 % 0.2 % 1.8 % 0 QAM 9.6 % 0.3 % 3.2 % 0 62.8 % 34.8 % 30.0 % 4.4 % QHS 75 % 58 % 38 % 2.6 % 66.8 %* 40.2 % 2.3 % (n=6) QHS 8.2 % 0.3 % 4.2 % 0 0.042 <0.001 <0.010 0.303 >0.2 0.002 <0.001 >0.2 0.0160 0.0581 >0.05 NS >0.05 NS >0.05 NS 6

Glargine vs Mixed insulin GALAPAGOS study Glargine n=258 Glargine w Glulisine n=197 Mixed QD n=159 Mixed BID n=287 HbA1c <7% 57.6% 24.4% 55.7% 50.9% Insulin Dose U/kg 0.38 0.60 0.14 0.46 Overall Hypoglycemia Events / Pt Year 22.6% 1.14 21.3% 1.2 28.6% 2.11 39% 3.4 Nocturnal Events / Pt Year 7.9% 0.37 6.6% 0.35 13.7% 1.10 21.6% 1 Aschner P, et al. J Diab Comp 2015;29(6):838 Mixed lispro versus glargine and detemir for type 2 diabetes Trials 24 36 wks Overall hypoglycemia rates were not significantly different Esposito K, et al. Diabetes Care 2012;35(12):2698 7

Esposito K, et al. Diabetes Care 2012;35(12):2698 Esposito K, et al. Diabetes Care 2012;35(12):2698 Degludec / Aspart vs Mixed Aspart Administered before breakfast and evening meal for 26 weeks Degludec w Aspart n=197 Mixed Aspart n=188 Weight +1.7kg +2.2kg Insulin dose 1.8units/kg 1.2units/kg Mean dose 38am 52pm 44am 54pm Fulcher GR, et al. Diabetes Care 2015:37(8):2084 8

32% lower rate with Deg/Asp CI 0.52 0.89 9.7 vs 14 episodes Per Pt Year 73% lower rate with Deg/Asp CI 0.19 1.30 0.7 vs 2.5 episodes Per Pt Year Switching from Basal Bolus to Mixed Aspart Dieuzedie G, et al. Primary care diabetes 2014;8(2):111 9

Switching from Basal Bolus to Mixed Aspart Glargine + Bolus NPH + Bolus Baseline 24wks P Baseline 24 wks P Hypoglycemia 5% 1.5% <0.01 10.8% 3.4% <0.001 Major 0.2% 0% P<0.05 1.2% 0% <0.001 Nocturnal 0.9% 0% P<0.01 3.7% 0.8% <0.001 Mean Wtkg 70.3 71.4 77.3 77 Dieuzedie G, et al. Primary care diabetes 2014;8(2):111 Rising prices of insulin Eli Lilly, Novo Nordisk, Sanofi Drug 2010 2015 price Humulin R U 500 325% Epipen 223% Levemir 169% Lantus 168% http://www.bloomberg.com/news/articles/2015 05 06/diabetes drugs compete with prices that rise in lockstep Similar prices 10

Good Rx Lantus $387 Levemir $417 Tresiba $552 Tuojeo $349 Humalog $506 Novolog $502 Humulin N $449 Novolin 70/30 $147 Humulin 70/30 $446 Novolog 70/30 $502 Humalog 75/25 $505 Advantages and disadvantages Basal Mixed insulins Initial daily dosing Initial daily dosing Cost with adding preprandial insulin 3 4 injections with adding preprandial Take prior to meals Stacking with 3 injections/day Basal Analogs 11

Case 37 yo male with increasing symptoms of hyperglycemia. Recent A1c 10.8% Metformin ER 500mg 2tabs twice daily Glipizide 5mg twice daily Indapamide 2.5mg daily Discuss your choice of insulin What is your recommendation? Basal analog NPH Mixed insulin NPH 70/30 Mixed analog Mixed insulin adjustments Glycemic control remains suboptimal AM 138 160 s Bedtime 250 s AM 130 140 s Before dinner 250 s AM 200 s Before dinner 150 s 12

Case 56 yo female with type 2 diabetes Metformin 1000mg twice daily Glargine 70 units twice daily Home glucose 300 s Discuss your plan regarding insulin adjustments Insulin initiation Assess for risk factors for hypoglycemia Assist patient with lifestyle goals and activities Injection sites / techinque Proper insulin storage / re suspension Recommendation Basal insulin: 10 15units daily increase gradually NPH Bedtime, Dinner, Morning NPH 70/30 before Dinner or largest meal Mixed analog before breakfast and dinner (might require 3 rd dose at noon) Consider Basal analogs Nocturnal / Morning hypoglycemia with NPH Pt requires assistance with insulin injections Seeking to de prescribe 13